Company underscores differentiated business model; reiterates confidence in its ability to drive above-market membership growth and increasing Adjusted EBITDA profitability1 through 2027, independent of Star ratings WILMINGTON, Del., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement company dedicated to bringing access to great healthcare to everyone on Medicare, today commented on the Centers for Medicare & ...

WILMINGTON, Del., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement company dedicated to bringing access to great healthcare to everyone on Medicare, today announced that it will release its financial results after the market closes on Tuesday, November 4, 2025. The Company’s management will host a webcast presentation at 5:00 p.m. Eastern Time on the same day to discuss the company’s business and financial ...

Company Overview - Clover Health Investments, Corp. is a physician enablement company focused on providing access to quality healthcare for Medicare beneficiaries [1][7] - The company utilizes a software platform called Clover Assistant to aggregate patient data, supporting clinical decision-making and improving health outcomes [7] Leadership Appointment - Dr. Ian Duncan has been appointed as the 2025-2026 President-Elect and Vice-Chair of the Society of Actuaries (SOA), recognizing his contributions to the actuarial profession and healthcare innovation [1][4] - Dr. Duncan's election is seen as a significant achievement for the actuarial profession, particularly in expanding its influence across various industries [4] Contributions to Healthcare - Dr. Duncan's work in predictive analytics and health risk adjustment has transformed the approach to value-based care, benefiting millions of patients [3] - His leadership at Clover Health has been instrumental in advancing healthcare analytics and risk adjustment practices [4][5] Educational Background - Dr. Duncan holds a Ph.D. in actuarial statistics from Heriot-Watt University and a graduate degree in economics from Balliol College, Oxford [6] Company Strategy - Clover Health aims to enhance patient outcomes and reduce healthcare costs through its data-driven technology platform, extending its benefits beyond its Medicare Advantage plans [7][8]

Clover Health Continues to Invest in Streamlining Provider Workflows and Reducing Administrative Burden Through Technology and Operational ImprovementsWILMINGTON, Del., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement company dedicated to bringing access to great healthcare to everyone on Medicare, is leveraging Availity, the nation’s largest real-time health information network, for a multi-phase initiati ...

Core Viewpoint - Clover Health positions itself as a leader in AI-enabled healthcare transformation, emphasizing the use of its proprietary AI platform, Clover Assistant, to enhance care delivery, particularly for seniors in underserved communities [1][2][6]. Group 1: AI and Healthcare Transformation - Clover Assistant is deployed across multiple states, serving thousands of healthcare providers and demonstrating measurable improvements in patient outcomes while reducing healthcare costs [2]. - The AI platform enables earlier disease detection, with data showing that diabetes can be diagnosed up to 3 years earlier and chronic kidney disease over 1.5 years earlier, leading to better health outcomes [7][22]. - AI is presented as a tool to enhance, not replace, the role of physicians, with the potential to improve care for all patients [4][14]. Group 2: Economic Impact and Cost Savings - AI-enabled care for congestive heart failure patients has resulted in 18% fewer hospitalizations and 25% fewer readmissions, while COPD patients experience 15% fewer hospitalizations and 18% lower 30-day readmissions [7][28]. - The Medical Cost Ratio for returning members whose doctors use Clover Assistant is over ten percent better than those who do not, allowing Clover to offer lower out-of-pocket costs for members [28]. Group 3: Empowering Providers - Clover Assistant acts as a central hub for a patient's care team, providing tailored views of patient data in specific clinical language, which helps combat physician burnout by automating tedious tasks [7][28]. - The platform is designed to integrate seamlessly into existing workflows, allowing practices to adopt it quickly with minimal training [13][19]. Group 4: Commitment to Responsible AI Use - The company advocates for the responsible use of AI, emphasizing that it should empower healthcare providers and improve patient care without denying or minimizing care [6][28]. - Clover Health calls for standardizing data interoperability to ensure AI can access comprehensive patient histories, which is essential for effective care delivery [29].

Summary of Clover Health Investments (CLOV) FY Conference - August 12, 2025 Company Overview - Clover Health is a tech-enabled insurance company focused on Medicare Advantage, experiencing growth despite industry challenges [3][6] - The company aims to deliver excellent clinical outcomes while providing broad access to healthcare for its members [3][6] Key Industry Insights - The Medicare Advantage market is substantial, valued at approximately $500 billion annually, with around 35 million enrollees in the U.S. [6] - Clover Health's unique approach includes a high percentage of members (97%) enrolled in PPO plans, allowing for wider access [7] Financial Performance - Membership is projected to grow by 32% in 2025, with revenue growth expected at 37% [7] - The company has maintained adjusted EBITDA profitability year-over-year, with flat profitability compared to the first half of the previous year [7][19] - Positive cash flow from operating activities was reported at approximately $84 million in 2024 [18] Technology and Clinical Outcomes - Clover Assistant, powered by machine learning and AI, enables physicians to diagnose and treat diseases earlier, leading to better health outcomes and lower total care costs [6][10] - Physicians using Clover Assistant can identify and treat chronic diseases significantly earlier, with diabetes treatment starting on average 36 months earlier [12] - The company boasts a high HEDIS score of 4.94 out of 5, indicating strong clinical quality [14] Business Model Differentiation - Clover Health's model emphasizes a clinical approach at the point of care, contrasting with traditional players that focus on back-office operations [15][16] - The company does not engage in traditional risk delegation, which is common among competitors [16] Growth Strategy - Clover Health is focused on expanding its presence in core markets: New Jersey, Georgia, South Carolina, and Texas, where it holds a 12% market share in New Jersey [20][21] - The company is also exploring opportunities to offer its technology to third-party providers and payers, enhancing its revenue model [22] Future Outlook - Membership and revenue growth are expected to accelerate, with a potential increase in profitability for 2026 [23] - The transition from a three-and-a-half-star to a four-star payment year is anticipated to add around 5% in premium fees [41] - The company is preparing for the upcoming Annual Enrollment Period (AEP) with a strategy focused on precise growth [33] Additional Considerations - Clover Health is investing in R&D and quality improvements while managing costs through efficiency programs [19] - The company is addressing higher utilization trends in Part D and expects a 40% increase in direct subsidies from CMS next year [28] This summary encapsulates the key points discussed during the conference, highlighting Clover Health's unique position in the Medicare Advantage market, its technological advancements, and its growth strategies moving forward.

Core Insights - Clover Health Investments reported Q2 2025 results with significant revenue growth, achieving GAAP sales of $477.6 million, exceeding analyst expectations of $468.3 million [1][5] - Despite revenue gains, profitability metrics weakened compared to Q2 2024, with a net loss per share of $(0.02) and an insurance benefits expense ratio (BER) of 88.4% [1][2] Financial Performance - Revenue increased by 34.0% year-over-year from $356.3 million in Q2 2024 to $477.6 million in Q2 2025 [2][5] - Adjusted net income from continuing operations fell to $16.7 million, down 53.5% from $35.9 million in Q2 2024 [2][6] - Adjusted EBITDA decreased by 52.8% to $17.1 million compared to $36.2 million in the previous year [2][6] - The insurance BER rose from 76.1% to 88.4%, indicating increased medical costs relative to premiums [2][7] Membership Growth - Medicare Advantage membership grew by 32% year-over-year, reaching 106,323 members as of June 30, 2025, up from 80,261 in the previous year [5][11] - The company aims to expand its membership in underserved markets and enhance the Clover Assistant platform [4][9] Strategic Initiatives - Clover Health is focusing on three main areas: expanding the Clover Assistant platform, growing MA plan membership, and developing Counterpart Health, a new technology and services business [4][9] - Management highlighted the importance of balancing rapid membership growth with the need to control rising medical costs [4][6] Outlook - The company updated its fiscal 2025 guidance, expecting average Medicare Advantage membership to reach between 104,000 and 108,000 [11] - Insurance revenue forecast remains at $1.8 billion to $1.875 billion, with adjusted EBITDA and net income targets set at $50 million to $70 million each [11] - The updated forecast for the Insurance BER is now projected to be between 88.5% and 89.5% for the full year [11]

Financial Data and Key Metrics Changes - The company reported a 32% year-over-year growth in Medicare Advantage membership, reaching over 106,000 members [20] - Insurance revenue increased by 34% to $470 million in Q2 2025, with year-to-date revenue at $927 million [20] - Adjusted EBITDA for Q2 2025 was $70 million, maintaining year-to-date adjusted EBITDA at $43 million [24] - GAAP net loss improved by $4 million year-to-date to $12 million [19][24] - The insurance benefit expense ratio (BER) was reported at 88.4%, up from 76.1% in 2024 [24] Business Line Data and Key Metrics Changes - The Medicare Advantage segment continues to show robust growth, with a focus on leveraging technology to enhance care management [5][8] - The company is experiencing elevated utilization levels in supplemental benefits and Part D, which are being monitored closely [21][22] Market Data and Key Metrics Changes - The company is insulated from broader industry pressures affecting Medicaid and ACA markets due to its focus on Medicare Advantage [10] - The Part D direct subsidy rate for 2026 is significantly higher than for 2025, indicating potential cost pressures that may alleviate in 2026 [12] Company Strategy and Development Direction - The company aims to achieve profitability, return to growth while sustaining profitability, and leverage its differentiated model for accelerated growth [6] - The focus remains on expanding the reach of Clover Assistant and enhancing member retention in existing markets [14] - The company is strategically positioned for a four-star payment year in 2026, which is expected to provide financial tailwinds [32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming membership growth season, potentially stronger than the current year [7] - The company is closely monitoring the impacts of the Part D IRA changes and anticipates variability in performance modeling [11] - Management believes that the technology-centric care delivery model will differentiate the company amidst industry pressures [12][13] Other Important Information - The company has maintained a strong cash position with $389 million in cash and investments as of Q2 2025 [26] - Days in claims payable decreased to 32 days, indicating normalization of claims inventory [25] Q&A Session Summary Question: How much conservatism is embedded in the raised guidance on the BER? - The increase in the BER guidance is primarily related to Part D and supplemental benefits, with initiatives in place to monitor these trends going forward [36][37] Question: When did the pressures start emerging, and how much was captured in the bids for next year? - The pressures, especially on Part D, have been tracked throughout the year, with adjustments made in pricing for bids [38][39] Question: What are the drivers for improvements in adjusted SG&A? - Improvements are mainly due to cost efficiencies and renegotiations with partners, reflecting the company's strong growth [41][42] Question: What response has been received from the COPD white paper? - The company plans to continue producing similar papers to highlight the benefits of using Clover Assistant in managing care [43][44] Question: Is the elevated cost trend localized or broad-based? - The elevated cost trends are not specific to new or returning members and are being monitored across the board [48][50] Question: How is the competitive landscape changing for the upcoming AEP? - Competitors are pulling back in certain areas, particularly within PPO networks, which may benefit the company due to its strong positioning [51][52]

Second Quarter 2025 Earnings Conference Call August 5, 2025 LGTMs: Date: Andrew T. (Input) Verbal LGTM 8/1 Peter K. LGTM 8/1 af Legal (Karen / Peter R.) LGTM 8/4 Accounting (#s confirm) LGTM (7/31 - Joe) Disclaimer This presentation and the accompanying oral presentation include forward-looking statements, including, without limitation, statements regarding future events and Clover Health Investments, Corp.'s ("Clover Health," "we," "our," or "us") expectations regarding Adjusted EBITDA, Adjusted Net income ...

Core Insights - Clover Health Investments, Corp. reported strong financial results for Q2 2025, highlighting significant membership and revenue growth, along with sustained profitability metrics [2][3][4] - The company's technology-first model is credited for driving better care management and improved health outcomes for members, particularly in Medicare Advantage plans [3][20] - Clover Health updated its full-year 2025 guidance, maintaining insurance revenue expectations while improving projections for adjusted SG&A and membership growth [10][4] Financial Performance - Q2 2025 insurance revenue reached $469.8 million, a 34.3% increase from $349.9 million in Q2 2024 [4][3] - Total revenues for Q2 2025 were $477.6 million, up 34% year-over-year [4][3] - Average Medicare Advantage membership increased by 31.8% year-over-year to 105,494 [4][3] - Adjusted net income from continuing operations was $16.7 million, down 53.5% from $35.9 million in Q2 2024 [4][3] - Adjusted EBITDA for Q2 2025 was $17.1 million, a decrease of 52.8% compared to $36.2 million in Q2 2024 [4][3] Membership and Revenue Guidance - The company expects average Medicare Advantage membership to be between 104,000 and 108,000 for the full year 2025, representing a 32% growth year-over-year at the midpoint [4][10] - Insurance revenue guidance for 2025 is maintained at $1.800 billion to $1.875 billion, indicating a 37% growth year-over-year at the midpoint [10][4] - Adjusted SG&A is projected to be between $335 million and $345 million, improving as a percentage of total revenues to 18% - 19% [10][4] Operational Metrics - The Insurance Benefits Expense Ratio (BER) for Q2 2025 was 88.4%, up from 76.1% in Q2 2024 [4][3] - The company reported a net loss from continuing operations of $10.6 million for Q2 2025, compared to a net income of $7.2 million in Q2 2024 [4][3] - Total cash, cash equivalents, and investments decreased by 19.4% to $389.3 million from $482.8 million year-over-year [4][3]